Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Bladder Cancer

August 30, 2017

Join Thomas W. Flaig, MD and Shandra Wilson, MD from University of Colorado Cancer Center as they present their expertise on a range of cases pertaining to bladder cancer.

Bladder cancer is the most common urological cancer. An estimated 76,960 new cases of urinary bladder cancer were diagnosed in the United States in 2016, with approximately 16,390 deaths occurring during this same period. The spectrum of bladder cancer includes non-muscle-invasive, muscle-invasive, and metastatic disease, and treatment of urothelial bladder cancer is influenced by the stage and grade of the cancer. Multimodality approaches and immunotherapies are demonstrating improved outcomes for patients with urothelial carcinomas. However, in order to effectively integrate these therapies into practice, clinician awareness of the importance of patient selection and subsequent monitoring for adverse events is essential.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas and Medivation, Inc., a Pfizer Company
  • AstraZeneca
  • Celgene Corporation
  • Gilead Sciences, Medical Affairs
  • Lilly
  • Novartis
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
  • Taiho Oncology
  • Takeda Oncology

This activity is supported by independent educational grants from:

  • AbbVie
  • Boehringer Ingelheim Pharmaceuticals, Inc.

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 1.00 CCM clock hours
  • 1.00 ACPE contact hours
  • 1.00 ANCC contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
08/30/2017
Course expires: 
10/27/2017
Event starts: 
08/30/2017 - 12:00pm
Event ends: 
08/30/2017 - 1:00pm
Cost:
$0.00

Thomas W. Flaig, MD
University of Colorado Cancer Center

Shandra Wilson, MD
University of Colorado Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity code: I00028181; Approval Number: 170003189

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-17-079-L01-P

Available Credit

  • 1.00 CCM clock hours
  • 1.00 ACPE contact hours
  • 1.00 ANCC contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Learning Objectives

Following this activity, participants should be able to:

  • Review the treatment options for patients with bladder cancer and how they relate to tumor stage and grade.
  • Describe potential similarities and differences among emerging immunotherapies for urothelial carcinoma.
  • Discuss the types of adverse events associated with traditional oncology treatment modalities and immunotherapy in patients with urothelial carcinoma.

Accreditation Period

Course opens: 
08/30/2017
Course expires: 
10/27/2017

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing